117 related articles for article (PubMed ID: 38719255)
1. Immune checkpoint inhibitor associated diarrhoea.
Al-Hussainy A; Adams J; Simmons J; Kennedy J
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719255
[TBL] [Abstract][Full Text] [Related]
2. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.
Prasanna T; McNeil CM; Nielsen T; Parkin D
Immunotherapy; 2018 Mar; 10(3):171-175. PubMed ID: 29370723
[TBL] [Abstract][Full Text] [Related]
3. Diarrhoea during checkpoint blockade, not always colitis.
Koldenhof JJ; Suijkerbuijk KPM
Eur J Cancer; 2017 Dec; 87():216-218. PubMed ID: 28993041
[No Abstract] [Full Text] [Related]
4. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
7. Immune-related colitis and pancreatitis treated with infliximab.
Ohwada S; Ishigami K; Yokoyama Y; Kazama T; Masaki Y; Takahashi M; Yoshii S; Yamano HO; Chiba H; Nakase H
Clin J Gastroenterol; 2023 Feb; 16(1):73-80. PubMed ID: 36414888
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
9. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB; Nielsen OH; Jacobsen S; Riis LB; Theile S; Bjerrum JT; Vilmann P; Johansen JS; Boisen MK; Eefsen RHL; Marie Svane I; Nielsen DL; Chen IM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096534
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab dose escalation triggered immune checkpoint inhibitor-induced colitis after 147 weeks of prolonged stable use in a patient with lung cancer: a case report.
Soma K; Nishida T; Osugi N; Morimura O; Adachi S; Fujii Y; Sugimoto A; Mukai K; Nakamatsu D; Matsumoto K; Yamamoto M
Clin J Gastroenterol; 2022 Feb; 15(1):128-133. PubMed ID: 34716545
[TBL] [Abstract][Full Text] [Related]
11. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
Gambichler T; Doerler M; Scheel CH
Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
[No Abstract] [Full Text] [Related]
12. Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
Yasuda Y; Urata Y; Tohnai R; Ito S; Kawa Y; Kono Y; Hattori Y; Tsuda M; Sakuma T; Negoro S; Satouchi M
Intern Med; 2018 May; 57(9):1269-1272. PubMed ID: 29279482
[TBL] [Abstract][Full Text] [Related]
13. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
Front Immunol; 2021; 12():788499. PubMed ID: 34956219
[TBL] [Abstract][Full Text] [Related]
14. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
15. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.
Kurozumi A; Takahashi H; Watanabe T; Iwasaki Y
Thorac Cancer; 2021 May; 12(10):1625-1628. PubMed ID: 33783978
[TBL] [Abstract][Full Text] [Related]
16. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis.
Alexander JL; Ibraheim H; Richards C; Shum B; Pavlidis P; Hunter N; Teare JP; Wotherspoon A; Furness A; Turajlic S; Pickering L; Larkin J; Speight A; Papa S; Powell N
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113896
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
18. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis].
Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E
Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141
[TBL] [Abstract][Full Text] [Related]
19. Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier.
Rasheed N; Anand R; Maddox M; Reyes C
BMJ Case Rep; 2023 Sep; 16(9):. PubMed ID: 37751983
[TBL] [Abstract][Full Text] [Related]
20. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
